| Q24186913 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q38235211 | Clinical effectiveness and comparative hospital costs of different platelet dose strategies |
| Q24187751 | Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q34061635 | Comparison of plateletpheresis on three continuous flow cell separators |
| Q81098195 | Consensus and controversies in platelet transfusion: trigger for indication, and platelet dose |
| Q24186359 | Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q30496886 | Dose of prophylactic platelet transfusions and prevention of hemorrhage |
| Q82697737 | Effect of donor variables on yield in single donor plateletpheresis by continuous flow cell separator |
| Q33377710 | Effects of high-yield thrombocytapheresis on the quality of platelet products |
| Q40409376 | Growth factors in haematological cancers |
| Q47968851 | Hemoglobin and Platelet Count Effect on Platelet Yields in Plateletpheresis |
| Q51982891 | Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. |
| Q33374336 | Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials |
| Q35131637 | Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. |
| Q33413326 | Milestones in understanding platelet production: a historical overview |
| Q33387735 | New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents. |
| Q33377901 | New insights and therapeutics for immune-mediated thrombocytopenia |
| Q79749964 | New thrombopoietic growth factors |
| Q33392855 | Platelet dose for prophylactic platelet transfusions |
| Q33347834 | Platelet dosing |
| Q56505470 | Platelet transfusions |
| Q33395509 | Platelet transfusions for patients with haematological malignancies: who needs them? |
| Q34708937 | Platelet transfusions: Impact on hemostasis, thrombosis, inflammation and clinical outcomes |
| Q24197779 | Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation |
| Q33349172 | Prophylactic platelet transfusions: which dose is the best dose? A review of the literature |
| Q33420059 | Romiplostim as a treatment for immune thrombocytopenia: a review |
| Q33343039 | Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. |
| Q33408850 | The biology of thrombopoietin and thrombopoietin receptor agonists |
| Q38073018 | The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions |
| Q35813075 | The top ten list of randomized controlled trials in transfusion medicine |
| Q87012764 | The utility of thromboelastometry in prophylactic platelet transfusion for hematological malignancies |
| Q33387153 | Thrombopoietin and platelet production in chronic immune thrombocytopenia |
| Q33344528 | Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions |
| Q33345267 | Thrombopoietin: from theory to reality |
| Q77309703 | [Hematopoietic growth factors and their side effects] |